Amarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Amarin (NASDAQ:AMRN) in a research note published on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Amarin Stock Up 1.8 %

Amarin stock opened at $0.45 on Monday. The company has a market capitalization of $184.02 million, a PE ratio of -4.98 and a beta of 1.82. The firm’s fifty day moving average is $0.53 and its 200 day moving average is $0.54. Amarin has a 12-month low of $0.35 and a 12-month high of $1.11.

Amarin’s stock is going to reverse split on the morning of Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 10th.

Amarin (NASDAQ:AMRN) last issued its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The firm had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. Sell-side analysts expect that Amarin will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Amarin

A number of large investors have recently modified their holdings of the company. Waterfront Wealth Inc. raised its holdings in Amarin by 181.4% during the fourth quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company’s stock worth $1,204,000 after buying an additional 1,599,956 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Amarin by 3.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company’s stock worth $650,000 after acquiring an additional 39,452 shares during the last quarter. Quinn Opportunity Partners LLC lifted its position in Amarin by 85.2% in the 4th quarter. Quinn Opportunity Partners LLC now owns 1,106,539 shares of the biopharmaceutical company’s stock valued at $537,000 after acquiring an additional 508,989 shares in the last quarter. AXA S.A. acquired a new position in Amarin during the 4th quarter valued at about $480,000. Finally, LCM Capital Management Inc increased its holdings in Amarin by 3.1% during the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 25,100 shares in the last quarter. 22.25% of the stock is currently owned by institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.